public meeting is designed to give interested parties the necessary information to understand more fully the background, purpose, and process of prototype development.

The meeting will be informal, i.e., any interested person may attend and participate in the discussion without prior notice to the agency. The meeting will begin with presentations by FDA, followed by a panel discussion. The panel will be composed of representatives from industry and from medical and pharmaceutical information professional groups. The final part of the meeting will be devoted to questions and comments from meeting attendees.

A transcript and summary of the meeting will be available from the Dockets Management Branch (address above) approximately 10 business days after the meeting at a cost of 10 cents per page.

Interested persons may submit to the Dockets Management Branch (address above) comments on the initial prototype and the meeting. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Written comments will be accepted until January 19, 1996, to permit time for all interested persons to submit data, information, or views on this subject.

Dated: September 29, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–24815 Filed 10–4–95; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

Statement of Organization, Functions, and Delegations of Authority

Part F of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Health Care Financing Administration (HCFA), (Federal Register, Vol. 59, No. 60, pp. 14628–14630, dated Tuesday, March 29, 1994) is amended to reflect the separation of HCFA support staff from the Provider Reimbursement Review Board (PRRB). It should be noted that this change does not affect the PRRB as prescribed by the Social Security Act.

The specific amendments to Part F are as follows:

- Section F.10. (Organization) is amended by deleting F.10.A.1. in its entirety and replacing it with the following:

1. Office of Hearings (FA–5)

- Provides staff support to the Provider Reimbursement Review Board (PRRB) and the Medicare Geographic Classification Review Board (MGCRB).
- Conducts Medicare and Medicaid hearings on behalf of the Secretary or the Administrator that are not within the jurisdiction of the Department Appeals Board, the Social Security Administration's Office of Hearings and Appeals, the PRRB, the MGCRB, or the States.
- Facilitates and supports hearings and assists members of the Board(s) in the preparation of final decision documents.

Dated: September 27, 1995.

Donna E. Shalala,

Secretary.

[FR Doc. 95–24761 Filed 10–4–95; 8:45 am]

BILLING CODE 4120–01–M

National Institutes of Health

AIDS Research Program Evaluation Working Group; Notice of Meeting

Notice is hereby given of the meeting of the NIH AIDS Research Program Evaluation Working Group Area Review Panel on Vaccine Research and Development on October 16, 1995 from 9:00 am to 5:00 pm at the Days Inn Crystal City, 2000 Jefferson Davis Highway, Arlington, Virginia. The meeting will be open to the public from 2:00 pm to 5:00 pm, and the closed portion will be from 9:00 am to 1 pm.

The NIH Revitalization Act of 1993 authorizes the Office of AIDS Research (OAR) to evaluate the AIDS research activities of NIH. The NIH AIDS Research Program Evaluation Working Group was established by the OAR to carry out this major evaluation initiative, reviewing and assessing each of the components of the NIH AIDS research endeavor to determine whether those components are appropriately designed and coordinated to answer the critical scientific questions to lead to better treatments, preventions, and a cure for AIDS. Six area Review Panels were also established to address the following research areas: Natural History and Epidemiology; Etiology and Pathogenesis; Clinical Trials; Drug Discovery; Vaccines; and Behavioral and Social Sciences Research.

The purpose of the meeting is to seek input from individuals and organizations interested in the evaluation of AIDS research in the areas of vaccine research and development. Examples of areas under consideration by the panel include identification of potential vaccine approaches, design and preclinical testing of candidate AIDS in animals—both small laboratory animals and nonhuman primates, clinical testing of candidate vaccines in human volunteers in phase I and II (safety and immunogenicity studies) and preparation for large scale testing in populations at high risk of acquiring HIV–1 infection. The NIH AIDS Research Program Evaluation Working Group will develop recommendations to be made to the Office of AIDS Research Advisory Council that address the overall NIH AIDS research initiatives, both intramural and extramural, and identify long-range goals in the relevant areas of science. These recommendations will provide the framework for future planning and budget development of the NIH AIDS research program.

There will be a closed session from 9:00 am to 1 pm to update the Panel members on privileged information on institute and center grant and contract portfolios.

The open session from 2 pm to 5:00 pm will begin with a brief overview of panel activities by members of the panel. The remainder of the meeting will be devoted to presentations from individuals and organizations. The session is open to the public; however, attendance may be limited by seat availability.

Comments should be confined to statements related to the current status of NIH AIDS research in the areas of AIDS vaccine research and development and recommendations for consideration by the panel in assessing and reviewing the relevant research in these areas.

Only one representative of an organization may present oral comments. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations must submit a letter of intent to present comments and three (3) typewritten copies of the presentation, along with a brief description of the organization represented, to the attention of Dr. Bonnie J. Mathieson, Office of AIDS Research, NIH, 31 Center Drive, MSC 2340, Building 31, Room 4C06, Bethesda, MD 20892–2340, (301) 496–4564, FAX: (301) 402–8638. Letters of intent and copies of presentations must be received no later than 4:00 pm EDT on Friday, October 13.

Any person attending the meeting who does not request an opportunity to speak in advance of the meeting will be